GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

GE

272.05

-1.46%↓

RTX

156.35

-0.77%↓

GEV.US

650.28

-1.91%↓

HON

220.91

+0.12%↑

UNP

222.99

+0.45%↑

Search

Verisk Analytics Inc

Închisă

SectorSectorul industrial

264.46 -1.34

Rezumat

Modificarea prețului

24h

Curent

Minim

262.11

Maxim

268.03

Indicatori cheie

By Trading Economics

Venit

22M

232M

Vânzări

17M

753M

P/E

Medie Sector

43.362

42.612

EPS

1.73

Randament dividend

0.54

Marjă de profit

30.85

Angajați

7,800

EBITDA

30M

416M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+14.65% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.54%

2.27%

Următoarele câștiguri

29 oct. 2025

Data viitoare de dividende

30 sept. 2025

Următoarea dată ex-dividende

15 sept. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.2B

41B

Deschiderea anterioară

265.8

Închiderea anterioară

264.46

Sentimentul știrilor

By Acuity

38%

62%

157 / 461 Clasament în Industrials

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Verisk Analytics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 21:42 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4 aug. 2025, 21:21 UTC

Câștiguri
Principalele dinamici ale pieței

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4 aug. 2025, 20:45 UTC

Câștiguri

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4 aug. 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 aug. 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4 aug. 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4 aug. 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4 aug. 2025, 21:30 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 21:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4 aug. 2025, 21:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4 aug. 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss $938M >RIG

4 aug. 2025, 20:25 UTC

Câștiguri

Transocean 2Q Loss/Shr $1.06 >RIG

4 aug. 2025, 20:18 UTC

Câștiguri

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4 aug. 2025, 20:15 UTC

Câștiguri

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4 aug. 2025, 20:14 UTC

Câștiguri

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4 aug. 2025, 20:13 UTC

Câștiguri

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4 aug. 2025, 20:09 UTC

Câștiguri

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4 aug. 2025, 20:06 UTC

Câștiguri

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4 aug. 2025, 20:01 UTC

Câștiguri

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4 aug. 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4 aug. 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4 aug. 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4 aug. 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Comparație

Modificare preț

Verisk Analytics Inc Așteptări

Obiectiv de preț

By TipRanks

14.65% sus

Prognoză pe 12 luni

Medie 311.73 USD  14.65%

Maxim 340 USD

Minim 290 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVerisk Analytics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

6

Cumpărare

6

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

294.51 / 309.9Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

157 / 461 Clasament în Sectorul industrial

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Verisk Analytics Inc

Verisk Analytics, Inc. provides data analytics and technology solutions to the insurance markets in the United States and internationally. It offers policy language, prospective loss costs, policy writing and rating rules, and various underwriting solutions for risk selection and segmentation, pricing, and workflow optimization; property- and auto- specific rating and underwriting information solutions that allows clients to understand, quantify, underwrite, mitigate, and avoid potential loss for risks; catastrophe modeling solutions, which enables companies to identify, quantify, and plan for the financial consequences of catastrophes for use by insurers, reinsurers, intermediaries, financial institutions, and governments. The company also provides life insurance solutions for transforming current workflows in life insurance underwriting, claim insights, policy administration, unclaimed property/equity, compliance and fraud detection, and actuarial and portfolio modeling; Marketing Solutions, such as compliant, real-time decisioning, profitability, and risk assessment for inbound consumer interactions; and international underwriting and claims solutions. In addition, it offers claims insurance solutions, which provides analytics in fraud detection, compliance reporting, subrogation liability assessment, litigation, and repair cost estimation and valuation solutions; and casualty solutions, such as compliance, casualty claims decision support, and workflow automation solutions. Further, the company supplies software to the specialty insurance market. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.